As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...
She thanks the NP for her treatment and the NP does not see the need to schedule any further follow-up visits. Initial Visit (1) Screen positive for possible insomnia. (2) Assign sleep log and ...
Common side effects include agitation, nausea, headache, loss of appetite, insomnia, and increased blood pressure ... have been evaluated most thoroughly, especially for the treatment of neuropathic ...
Researchers evaluated 72 adults with chronic insomnia disorder who had Pittsburgh ... and fatigue that could serve as a promising nonpharmacological treatment alternative. The stated objective ...
substantially expanding a growing body of evidence supporting its safety and efficacy for chronic insomnia. On the primary endpoint of improvement in the Pittsburgh Sleep Quality Index (PSQI), the ...